MissionIR would like to highlight
Cardium Therapeutics (
NYSE: CXM), a health sciences and regenerative medicine company focused on the acquisition and strategic development of new and innovative bio-medical product opportunities and businesses with the potential to address significant unmet medical needs that have definable pathways to commercialization, partnering and other economic monetizations. Cardium's current medical opportunities portfolio, which is focused on health sciences and regenerative medicine, includes the Tissue Repair Company, Cardium Biologics, as well as healthy lifestyle nutritional products.
In the company’s news,
Cardium Therapeutics’ subsidiary
To Go Brands healthy nutraceutical supplement business is complimentary to the company’s overarching mission of meeting unmet medical needs as part of an individual’s overall health and wellness.
Cardium in October 2012 acquired the assets, business, and product portfolio of
To Go Brands, which develops and markets more than 25 products including nutraceutical powder mixes, supplements, and chews to support healthy lifestyles.
The brand’s
Healthy To Go product line offers a host of healthy product offerings distributed through mass food and drug channels at retailers such as Whole Foods, CVS, Kroger, GNC, Vitamin Shoppe, and more.
Within Cardium’s medical opportunities portfolio is its lead commercial product, Excellagen®, topical gel for wound care management. Excellagen is FDA-approved for the marketing and sale in the United States. In addition to its plans to advance Excellagen’s commercial reach in the U.S. and internationally, Cardium plans to develop new extensions for additional wound care applications, and its working to achieve regulatory approval for the marketing and sale of the product in South Korea and the European Union.
The company’s lead clinical development product candidate Generx® is a DNA-based angiogenic biologic designed to treat patients with myocardial ischemia due to coronary artery disease. Cardium recently initiated its phase 3 registration study for Generx in Russia.
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
To sign up for The MissionIR Report, please visit http://MissionIR.com
To connect with MissionIR via Facebook, please visit http://Facebook.com/MissionIR
To connect with MissionIR via Twitter, please visit http://Twitter.com/MissionIR
Please read FULL disclaimer on the MissionIR website: http://Disclaimer.MissionIR.com
Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.
